CCL21 and neoplasm: Recently tenascin-C was shown to contribute to the immune-suppressive microenvironment of the tumor stroma through integrin α9β1 inducing CCL21 (in lymphatic endothelial cells) and TLR4 regulating CCR7 (in CD11c+/dendritic cells) (18, 19).